Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 4
Submit an article Journal homepage
341
Views
21
CrossRef citations to date
0
Altmetric
Review

Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development

P Noel Barrett Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau, Austria. [email protected]; Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau, Austria. [email protected]
,
Daniel Portsmouth Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau, Austria; Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau, Austria
&
Hartmut J Ehrlich Global R&D, Baxter BioScience, IZD Tower, Wagramerstraße 17–19, A-1220 Vienna, Austria; Global R&D, Baxter BioScience, IZD Tower, Wagramerstraße 17–19, A-1220 Vienna, Austria
Pages 395-413 | Published online: 09 Jan 2014

References

  • Watanabe Y, Ibrahim MS, Suzuki Y, Ikuta K. The changing nature of avian influenza A virus (H5N1). Trends Microbiol. 20(1), 11–20 (2012).
  • Herfst S, Schrauwen EJ, Linster M et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336(6088), 1534–1541 (2012).
  • Imai M, Watanabe T, Hatta M et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486(7403), 420–428 (2012).
  • Imai M, Kawaoka Y. The role of receptor binding specificity in interspecies transmission of influenza viruses. Curr. Opin. Virol. 2(2), 160–167 (2012).
  • Watanabe Y, Ibrahim MS, Ellakany HF et al. Acquisition of human-type receptor binding specificity by new H5N1 influenza virus sublineages during their emergence in birds in Egypt. PLoS Pathog. 7(5), e1002068 (2011).
  • Broberg E, Nicoll A, Amato-Gauci A. Seroprevalence to influenza A(H1N1) 2009 virus – where are we? Clin. Vaccine Immunol. 18(8), 1205–1212 (2011).
  • Shrestha SS, Swerdlow DL, Borse RH et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin. Infect. Dis. 52(Suppl. 1), S75–S82 (2011).
  • Dawood FS, Iuliano AD, Reed C et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect. Dis. 12(9), 687–695 (2012).
  • Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 442(7101), 448–452 (2006).
  • Perdue ML, Arnold F, Li S et al. The future of cell culture-based influenza vaccine production. Expert Rev. Vaccines 10(8), 1183–1194 (2011).
  • Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect. Dis. 8(10), 650–658 (2008).
  • Palache B, Krause R. Progress with human H5N1 vaccines: a perspective from industry. Expert Rev. Vaccines 8(4), 391–400 (2009).
  • Rebmann T, Zelicoff A. Vaccination against influenza: role and limitations in pandemic intervention plans. Expert Rev. Vaccines 11(8), 1009–1019 (2012).
  • Leroux-Roels I, Leroux-Roels G. Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev. Vaccines 8(4), 401–423 (2009).
  • Committee for Proprietary Medicinal Products. Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. Report No.: CPMP/BWP/214/96. European Agency for the Evaluation of Medicinal Products (EMEA), London, UK (1997).
  • Johansson BE, Cox MM. Influenza viral neuraminidase: the forgotten antigen. Expert Rev. Vaccines 10(12), 1683–1695 (2011).
  • Marcelin G, Bland HM, Negovetich NJ et al. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J. Infect. Dis. 202(11), 1634–1638 (2010).
  • Marcelin G, DuBois R, Rubrum A, Russell CJ, McElhaney JE, Webby RJ. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. PLoS ONE 6(10), e26335 (2011).
  • Doherty PC, Turner SJ, Webby RG, Thomas PG. Influenza and the challenge for immunology. Nat. Immunol. 7(5), 449–455 (2006).
  • McKinstry KK, Strutt TM, Swain SL. Hallmarks of CD4 T cell immunity against influenza. J. Intern. Med. 269(5), 507–518 (2011).
  • McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176(10), 6333–6339 (2006).
  • Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev. Vaccines 8(5), 607–618 (2009).
  • Barrett PN, Portsmouth D, Ehrlich HJ. Developing cell culture-derived pandemic vaccines. Curr. Opin. Mol. Ther. 12(1), 21–30 (2010).
  • Hess RD, Weber F, Watson K, Schmitt S. Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines. Vaccine 30(17), 2715–2727 (2012).
  • Reynales H, Astudillo P, de Valliere S et al A prospective observational safety study on MF59((R)) adjuvanted cell culture-derived vaccine, Celtura((R)) during the A/H1N1 (2009) influenza pandemic. Vaccine 30(45), 6436–6443 (2012).
  • Kistner O, Barrett PN, Mundt W et al. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16(9-10), 960–968 (1998).
  • Kistner O, Howard MK, Spruth M et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25(32), 6028–6036 (2007).
  • Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol. Chem. 389(5), 569–577 (2008).
  • Howard MK, Sabarth N, Savidis-Dacho H et al. H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS ONE 6(8), e23791 (2011).
  • Sabarth N, Howard MK, Savidis-Dacho H, van Maurik A, Barrett PN, Kistner O. Comparison of single, homologous prime-boost and heterologous prime-boost immunization strategies against H5N1 influenza virus in a mouse challenge model. Vaccine 28(3), 650–656 (2010).
  • Sabarth N, Savidis-Dacho H, Schwendinger MG et al. A cell culture-derived whole-virus H5N1 vaccine induces long-lasting cross-clade protective immunity in mice which is augmented by a homologous or heterologous booster vaccination. Vaccine 30(37), 5533–5540 (2012).
  • van Maurik A, Sabarth N, Dacho HS et al. Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination. Vaccine 28(7), 1778–1785 (2010).
  • Geeraedts F, Bungener L, Pool J, ter Veer W, Wilschut J, Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respi. Viruses 2(2), 41–51 (2008).
  • Hagenaars N, Mastrobattista E, Glansbeek H et al. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine 26(51), 6555–6563 (2008).
  • Geeraedts F, Goutagny N, Hornung V et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog. 4(8), e1000138 (2008).
  • Nicholson KG, Tyrrell DA, Harrison P et al. Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J. Biol. Stand. 7(2), 123–136 (1979).
  • Ehrlich HJ, Müller M, Oh HM et al.; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358(24), 2573–2584 (2008).
  • Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370(9587), 580–589 (2007).
  • Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343–1351 (2006).
  • Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367(9523), 1657–1664 (2006).
  • Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19(13–14), 1732–1737 (2001).
  • Ehrlich HJ, Müller M, Fritsch S et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J. Infect. Dis. 200(7), 1113–1118 (2009).
  • Tambyah PA, Wilder-Smith A, Pavlova BG et al. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 30(2), 329–335 (2012).
  • van der Velden MV, Aichinger G, Pöllabauer EM et al. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. Vaccine 30(43), 6127–6135 (2012).
  • Committee for Human Medicinal Products. Guideline on Dossier Structure and Content for Pandemic Influenza Vaccine Marketing Authorisation Application. Report No.: EMEA/CPMP/VEG/4717/2003- Rev.1. European Medicines Agency, London, UK (2008).
  • Fritz R, Sabarth N, Kiermayr S et al. A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J. Infect. Dis. 205(1), 28–34 (2012).
  • Crowe BA, Brühl P, Gerencer M et al. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine 29(2), 166–173 (2010).
  • Galli G, Medini D, Borgogni E et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106(10), 3877–3882 (2009).
  • Pedersen GK, Madhun AS, Breakwell L et al. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J. Infect. Dis. 206(2), 158–166 (2012).
  • Kistner O, Crowe BA, Wodal W et al. A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models. PLoS ONE 5(2), e9349 (2010).
  • Loew-Baselli A, Pavlova BG, Fritsch S et al. A non-adjuvanted whole-virus H1N1 pandemic vaccine is well tolerated and highly immunogenic in children and adolescents and induces substantial immunological memory. Vaccine 30(41), 5956–5966 (2012).
  • Ehrlich HJ, Müller M, Kollaritsch H et al. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. Vaccine 30(30), 4543–4551 (2012).
  • Twenty-second pandemic pharmacovigilance update. European Medicines Agency, 2010. Report No.: EMA/527985/2010.
  • Labrosse B, Tourdjman M, Porcher R et al. Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay. PLoS ONE 5(6), e11036 (2010).
  • Lemaitre M, Leruez-Ville M, De Lamballerie XN et al. Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus. Clin. Microbiol. Infect. 17(5), 732–737 (2011).
  • Parkman PD, Hopps HE, Rastogi SC, Meyer HM Jr. Summary of clinical trials of influenza virus vaccines in adults. J. Infect. Dis. 136, S722–S730 (1977).
  • Lagler H, Grabmeier-Pfistershammer K, Touzeau-Romer V et al. Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals. PLoS ONE 7(5), e36773 (2012).
  • Lagler H, Tobudic S, Ramharter M et al. Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation. Vaccine 30(48), 6864–6870 (2012).
  • Lagler H, Wenisch JM, Tobudic S et al. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination. Vaccine 29(40), 6888–6893 (2011).
  • Nicholson KG, Abrams KR, Batham S et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect. Dis. 11(2), 91–101 (2011).
  • Waddington CS, Walker WT, Oeser C et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months–12 years: open label, randomised, parallel group, multicentre study. BMJ 340, c2649 (2010).
  • Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis. 176(Suppl. 1), S20–S23 (1997).
  • Vesikari T, Block SL, Guerra F et al. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Pediatr. Infect. Dis. J. 31(5), 494–500 (2012).
  • Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J. Infect. Dis. 204(12), 1879–1885 (2011).
  • Fusaro A, Monne I, Salviato A et al. Phylogeography and evolutionary history of reassortant H9N2 viruses with potential human health implications. J. Virol. 85(16), 8413–8421 (2011).
  • Matrosovich MN, Krauss S, Webster RG. H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity. Virology 281(2), 156–162 (2001).
  • Sorrell EM, Wan H, Araya Y, Song H, Perez DR. Minimal molecular constraints for respiratory droplet transmission of an avian-human H9N2 influenza A virus. Proc. Natl Acad. Sci. USA 106(18), 7565–7570 (2009).
  • Sun Y, Qin K, Wang J et al. High genetic compatibility and increased pathogenicity of reassortants derived from avian H9N2 and pandemic H1N1/2009 influenza viruses. Proc. Natl Acad. Sci. USA 108(10), 4164–4169 (2011).
  • Wan H, Sorrell EM, Song H et al. Replication and transmission of H9N2 influenza viruses in ferrets: evaluation of pandemic potential. PLoS ONE 3(8), e2923 (2008).
  • Wodal W, Falkner FG, Kerschbaum A et al. A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate. Vaccine 30(31), 4625–4631 (2012).
  • Romanova J, Krenn BM, Wolschek M et al. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine. PLoS ONE 4(6), e5984 (2009).
  • Centers for Disease Control and Prevention. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2012–13 Influenza Season. MMWR Morb. Mortal. Wkly Rep. 61, 613–618 (2012).
  • Mayrhofer J, Coulibaly S, Hessel A et al. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J. Virol. 83(10), 5192–5203 (2009).
  • Wu CY, Yeh YC, Yang YC et al. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS ONE 53, e9784 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.